| abstract |
The present disclosure provides a combination of a chromene compound having a structure of formula (I) or a pharmaceutically acceptable salt and a second compound, and the second compound may be selected from PD‑1 inhibitors, PD‑L1 inhibitors, CTLA‑4 Inhibitors, OX-40 agonists, CD137 agonists, LAG-3 inhibitors, IDO inhibitors, bispecific proteins, EGFR inhibitors, HER2 inhibitors and immunostimulatory therapeutics, and use of said combinations to treat Or ways to prevent cancer. |